ombitasvir + paritaprevir + ritonavir + sofosbuvir + ribavirin

This is an oral combination regimen containing five direct-acting antiviral agents: **ombitasvir** (an HCV NS5A inhibitor), **paritaprevir** (HCV NS3/4A protease inhibitor), **ritonavir** (CYP3A inhibitor used to boost paritaprevir), **sofosbuvir** (HCV NS5B nucleotide polymerase inhibitor), and **ribavirin** (a nucleoside analog antiviral with broad-spectrum activity). Each component inhibits a different stage in the hepatitis C virus (HCV) lifecycle, resulting in a potent, multitargeted antiviral effect. While regimens such as Viekira Pak (ombitasvir, paritaprevir, ritonavir, dasabuvir) with or without ribavirin and sofosbuvir-containing combinations are FDA approved for genotype 1 HCV, the precise five-drug combination listed here is not an approved or marketed formulation, but represents a theoretical or investigational combination for chronic HCV, particularly genotype 1 infection, with the potential for high sustained virologic response rates and applicability to difficult-to-treat HCV populations[1][2][4][5].

Brand names

Viekira Pak with ribavirin

Other names

SOF + OBV/PTV/r + RBVsofosbuvir plus ombitasvir/paritaprevir/ritonavir plus ribavirinritonavir-Beni-Suef University-chronic hepatitis C